 PETACH TIKVA, Israel--BUSINESS WIRE--Can-Fite BioPharma Ltd. NYSE American: CANF TASE:CFBI, a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced new data from the Phase II advanced liver cancer study including overall survival of nearly 4 years in two patients who are under namodenoson treatment. Additional findings show disappearance of ascites, normal liver function and good quality of life. In 